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A B S T R A C T
Background: Selenium, an essential trace element, is incorporated into selenoproteins with a wide range of
health eﬀects. Selenoproteins may reach repletion at a plasma selenium concentration of ~ 125 µg/L, at which
point the concentration of selenoprotein P reaches a plateau; whether sustained concentrations higher than this
are beneﬁcial, or indeed detrimental, is unknown.
Objective: In a population of relatively low selenium status, we aimed to determine the eﬀect on mortality of
long-term selenium supplementation at diﬀerent dose levels.
Design: The Denmark PRECISE study was a single-centre, randomised, double-blinded, placebo-controlled,
multi-arm, parallel clinical trial with four groups. Participants were 491 male and female volunteers aged 60–74
years, recruited at Odense University Hospital, Denmark. The trial was initially designed as a 6-month pilot
study, but supplemental funding allowed for extension of the study and mortality assessment. Participants were
randomly assigned to treatment with 100, 200, or 300 µg selenium/d as selenium-enriched-yeast or placebo-
yeast for 5 years from randomization in 1998–1999 and were followed up for mortality for a further 10 years
(through March 31, 2015).
Results: During 6871 person-years of follow-up, 158 deaths occurred. In an intention-to-treat analysis, the ha-
zard ratio (95% conﬁdence interval) for all-cause mortality comparing 300 µg selenium/d to placebo was 1.62
(0.66, 3.96) after 5 years of treatment and 1.59 (1.02, 2.46) over the entire follow-up period. The 100 and
200 µg/d doses showed non-signiﬁcant decreases in mortality during the intervention period that disappeared
after treatment cessation. Although we lacked power for endpoints other than all-cause mortality, the eﬀects on
cancer and cardiovascular mortality appeared similar.
Conclusions: A 300 µg/d dose of selenium taken for 5 years in a country with moderately-low selenium status
increased all-cause mortality 10 years later. While our study was not initially designed to evaluate mortality and
the sample size was limited, our ﬁndings indicate that total selenium intake over 300 µg/d and high-dose se-
lenium supplements should be avoided.
1. Introduction
Selenium is a trace element essential for human health. As seleno-
cysteine, it is incorporated into 25 human selenoproteins with a wide
range of health eﬀects, most notably the ability to reduce oxidative
stress and inﬂammation [1,2]. Reinforcing the importance of seleno-
proteins, single nucleotide polymorphisms in a number of selenopro-
teins are linked to age-related disorders such as cardiovascular disease
(CVD) and a wide range of cancers [1]. The concentration of seleno-
protein P, and probably of all selenoproteins, plateaus when plasma
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selenium concentration reaches ~ 125 µg/L [3]; it is unclear whether
selenium supplementation that results in higher plasma concentration,
particularly if sustained, has any beneﬁcial, or indeed detrimental, ef-
fects.
The US Third National Health and Nutrition Examination Survey
(NHANES) showed a U-shaped association between serum selenium and
all-cause mortality, with minimal mortality at a concentration of ~
135 µg/L [4]. Of six other observational studies [2,5–9], ﬁve found an
inverse association between selenium status or intake and mortality
[2,5–8] while one found no eﬀect [9]. These studies are still consistent
with a U-shaped dose-response as they were conducted in populations
with low [5–7] or relatively low [2,8], serum-selenium concentration or
selenium intake and provide no information on mortality at high serum-
selenium concentrations [4].
Only two randomised controlled trials of selenium as a single nu-
trient had a mortality outcome; both were carried out in the US. In the
Nutritional Prevention of Cancer trial in 1312 participants, 200 µg/d
selenium (as high-selenium yeast) increased mean plasma selenium
from 114 to 190 µg/L and resulted in a non-signiﬁcant 21% reduction in
all-cause mortality, a signiﬁcant 52% reduction in cancer mortality
[10], but no eﬀect on cardiovascular mortality [11] over a 6-to-8-year
follow-up. In the Selenium and Vitamin E Cancer Prevention Trial
(SELECT) conducted in 35,533 men, 200 µg/d selenium (as seleno-
methionine) increased mean serum selenium from 138 to 252 µg/L with
no eﬀect on all-cause or cancer mortality after 5.5 and 8 years of follow-
up [12,13]. No randomised trial data are available on the long-term
eﬀect of selenium supplementation on mortality in populations of re-
latively low selenium status; our aim was to provide such data.
We report here the ﬁndings of a double-blind, randomised, con-
trolled trial of long-term selenium supplementation and mortality in
Denmark, a country of moderately-low selenium status. We randomised
participants to treatment with selenium (100, 200, and 300 µg/d) or
placebo for 5 years and followed them up, post-treatment, for a further
10 years.
2. Subjects and methods
The methods of this pilot study, previously described in detail [14],
are summarized below.
2.1. Study design and sample size
The Denmark PRECISE pilot study (ClinicalTrials.gov ID:
NCT01819649) was a single-centre, randomised, double-blinded, pla-
cebo-controlled, multi-arm, parallel clinical trial with four groups (al-
location ratio 1:1:1:1) run from Odense University Hospital, Denmark
[14,15]. Denmark PRECISE was one of two pilot studies for the pro-
posed international PRECISE trial of selenium in cancer prevention; the
other was carried out in the UK [16–18]. No formal power calculations
were performed a priori; the sample size was set at 500 participants,
which was considered suﬃcient to assess whether recruitment, ad-
herence, and retention during follow-up would be suﬃcient for a large
trial.
2.2. Change to outcomes
While the corresponding UK trial was terminated after 6 months, as
planned, extended funding enabled the Danish pilot study intervention
to continue for 5 years in the hope that funding for the proposed in-
ternational PRECISE trial would become available. Though such
funding was never secured, participant follow-up in the Danish cohort
was continued for a further 10 years for mortality ascertainment. It
should be noted, however, that mortality was not a planned endpoint
when the trial was initiated. The trial protocol and subsequent
amendments are available on-line [19].
2.3. Participants
From November 1998 to June 1999, 2897 potential participants,
males and females aged 60–74 years, from the County of Funen,
Denmark were invited to take part in the trial; 630 accepted the in-
vitation to be screened for inclusion at Odense University Hospital.
Exclusion criteria were: a Southwest Oncology Group performance-
status score> 1, indicating impairment in general well-being and ac-
tivities of daily life; active liver or kidney disease; previous diagnosis of
cancer (excluding non-melanoma skin cancer); diagnosed HIV infec-
tion; receiving immunosuppressive therapy; being unable to understand
written/spoken information; and receiving ≥ 50 μg/d of selenium
supplements in the previous 6 months.
2.4. Randomization
Randomization was computer-generated, blocked and non-stratiﬁed
[14]. Participating couples living at the same address were allocated to
the same intervention. Participants, research staﬀ and investigators
were blinded to treatment assignment [14].
2.5. Ethics committee (IRB) approval
The regional Data Protection Agency and Scientiﬁc Ethics
Committees of Vejle and Funen counties approved the study prior to
data collection (Journal nr. 19980186).
2.6. Intervention and procedures
Participants deemed suitable for inclusion provided blood samples
and were given yeast tablets for an open-label 4-week placebo run-in
phase. Those (n=491) who met the inclusion criteria, displayed good
adherence in the placebo run-in phase, and gave written, informed
consent, were randomised to 0 (placebo-yeast), 100, 200, or 300 μg/d
of Se as Se-enriched yeast (SelenoPrecise© Pharma Nord, Vejle,
Denmark) (Fig. 1). Participant evaluation was carried out at Odense
University Hospital at baseline, 6, 12, 18 months, 2, 3 and 5 years, as
previously described in detail [14]. The intervention was delivered for
5 years and participants were followed up, post-treatment, for an ad-
ditional 10 years for mortality ascertainment.
2.7. Baseline characteristics
Demographic characteristics, smoking status, height, weight, and
supplement use were collected at baseline. Medications used were ob-
tained from medical records. Morbidity data were obtained from the
Danish National Patient Registry which has records of major and sec-
ondary diagnoses for all in-patient discharges since 1977 and all
emergency and outpatient contacts since 1995 [20]. The Charlson co-
morbidity index was computed by adding 19 comorbid conditions di-
agnosed prior to randomization [21].
2.8. Selenium measurement
As previously described in detail [14], total Se was measured
gravimetrically (ng/g) in lithium-heparin plasma at LGC Limited,
Teddington, United Kingdom, by inductively coupled-plasma mass
spectrometry at baseline, 6-months and 5-years. Analysis of a matrix-
certiﬁed reference material indicated good accuracy of the method. The
intra-assay coeﬃcients of variation (CVs) ranged from 0.5% for samples
of high-Se concentration to 3% for samples of low-Se concentration.
The inter-assay CV was 3.4%.
2.9. Outcomes: mortality ascertainment
Study participants were followed up for mortality from the date of
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randomization in 1998–1999 through March 31, 2015. Vital status and
date of death were obtained from the Danish Civil Registration System
which has recorded all deaths in residents in Denmark since 1968 [22].
Information on the underlying cause of death was obtained from the
Danish Registry of Causes of Death [23] through December 31, 2010
and from participant medical charts from January 1, 2011. Cause of
death was classiﬁed according to the 10th Revision of the International
Classiﬁcation of Diseases as death due to cancer (codes C00–C97), CVD
(I00–I99), and all other causes. All participants not found to be de-
ceased were conﬁrmed to be alive and resident in Denmark by March
31, 2015 in the Danish Civil Registration System.
2.10. Power calculations for intention-to-treat mortality analysis
Although no formal sample size determinations were performed a
priori in the original study design, we carried out ad-hoc power calcu-
lations for the present intention-to-treat mortality analysis. For the
average sample size of 123 participants in each randomised treatment
group, the observed cause-speciﬁc mortality risks over follow-up in the
placebo group (Fig. 2), and an unadjusted two-sided signiﬁcance level
of 0.05, the power to detect underlying increases in risk of 50% and
100% after 5 years of intervention comparing any active treatment
group with placebo was 13.9% and 35.7% for all-cause mortality, 8.7%
and 17.6% for cancer mortality, and 8.1% and 15.5% for CVD mor-
tality. After the entire 16-year follow-up period, the power to detect the
same underlying risk rose to 62.7% and 99.5% for all-cause mortality,
29.7% and 76.3% for cancer mortality, and 21.0% and 57.1% for CVD
mortality. Thus, the study was acceptably powered to detect a 50%
increased risk for all-cause mortality and a two-fold increased risk for
cancer and CVD mortality over the entire follow-up, but underpowered
to detect such risk increases during the initial 5 years of intervention.
2.11. Statistical analysis
All trial participants were assigned to their randomised treatment
group irrespective of compliance (intention-to-treat analysis).
Cumulative mortality was estimated using Kaplan-Meier methods and
compared with the generalized Wilcoxon test. Hazard ratios for mor-
tality and 95% conﬁdence intervals (CIs) comparing the three active
treatment groups with placebo were estimated using Cox proportional
hazards models. We obtained smooth estimates of cumulative mortality
curves by ﬁtting spline-based parametric survival models [24]. These
models were used to estimate mortality risks and 95% CIs at 5, 10, and
15 years of follow-up for each treatment group, as well as to calculate
Assessed for eligibility (n = 2,897)
Randomized (n = 491)
Excluded (n = 2,406)
Declined to participate: 2,267
Did not meet inclusion criteria: 63
Did not complete placebo run-in: 5
Withdrew consent: 38
Unknown/personal reasons: 33
Allocated to placebo (n = 126)
Received allocation: 126
Allocated to 300 µg/d (n = 119)
Received allocation: 119
Allocated to 200 µg/d (n = 122)
Received allocation: 122
Allocated to 100 µg/d (n = 124)
Received allocation: 124
Drop-outs during 5 years of 
treatment (n = 30)
Adverse events: 5
Adverse reactions: 6
Withdrew consent: 10
Unknown/personal reasons: 9
Drop-outs during 5 years of 
treatment (n = 27)
Adverse events: 13
Adverse reactions: 5
Withdrew consent: 5
Unknown/personal reasons: 4
Drop-outs during 5 years of 
treatment (n = 30)
Adverse events: 11
Adverse reactions: 8
Withdrew consent: 4
Unknown/personal reasons: 7
Drop-outs during 5 years of 
treatment (n = 21)
Adverse events: 6
Adverse reactions: 6
Non-compliance: 1
Withdrew consent: 3
Unknown/personal reasons: 5
Alive at the end of 5-year 
treatment (n = 118)
Alive at the end of 5-year 
treatment (n = 118)
Alive at the end of 5-year 
treatment (n = 117)
Alive at the end of 5-year 
treatment (n = 107)
Deaths during 5 years of 
treatment (n = 8)
Cancer: 4
CVD: 2
Other causes: 2
Deaths during 5 years of 
treatment (n = 6)
Cancer: 3
CVD: 2
Other causes: 1
Deaths during 5 years of 
treatment (n = 5)
Cancer: 3
CVD: 1
Other causes: 1
Deaths during 5 years of 
treatment (n = 12)
Cancer: 8
CVD: 4
Deaths after 5 years of 
treatment (n = 27)
Cancer: 12
CVD: 9
Other causes: 6
Deaths after 5 years of 
treatment (n = 35)
Cancer: 17
CVD: 5
Other causes: 13
Deaths after 5 years of 
treatment (n = 30)
Cancer: 12
CVD: 10
Other causes: 6
Unknown cause: 2
Deaths after 5 years of 
treatment (n = 35)
Cancer: 16
CVD: 10
Other causes: 8
Unknown cause: 1
Alive at the end of follow-up
(n = 91)
Alive at the end of follow-up
(n = 83)
Alive at the end of follow-up
(n = 87)
Alive at the end of follow-up
(n = 72)
Fig. 1. Study ﬂow diagram. CVD denotes cardiovascular disease.
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cumulative risk diﬀerences and cumulative hazard ratios over time,
comparing the three active treatment groups with placebo.
We evaluated treatment-eﬀect modiﬁcation across baseline sub-
groups speciﬁed by age (< 65, ≥ 65 years), sex, smoking status (non-
current, current), body-mass index (< 25, ≥ 25 kg/m2), Charlson
comorbitity index (0, 1–2), number of medications (0, 1–3) and plasma
selenium concentration (< 80, ≥ 80 ng/g), including main terms and
interactions between treatment group and the corresponding covariates
in Cox proportional hazards models. We tested for interaction by using
joint Wald tests for interaction coeﬃcients. The signiﬁcance level was
set at 0.05; all reported P values were two-sided and not adjusted for
multiple testing since only three tests were performed in the main
analyses to compare simultaneously cause-speciﬁc mortality curves for
the four treatment groups throughout the entire follow-up period, one
test for all-cause mortality and two additional tests for cancer and CVD
mortality as major contributing causes. Statistical analyses were per-
formed in Stata, version 14 (Stata Corp) and graphics were produced in
R, version 3 (R Foundation for Statistical Computing).
The study was overseen by a safety and monitoring committee with
representatives from all organizations involved.
3. Results
The mean (SD) age and plasma selenium concentration of the 491
randomised participants at baseline were 66.1 (4.1) years and 86.5
(16.3) ng/g, respectively (measurements were made gravimetrically,
but ng/g can be converted to µg/L by multiplying by 1.027). Only 49
participants (10.0%) presented with comorbid conditions at baseline
and 56 (11.4%) were on more than one medication. There were no
meaningful imbalances at baseline between treatment groups in plasma
selenium concentration or other participant characteristics (Table 1).
A total of 108 participants dropped out before completing the 5-year
treatment period due to non-fatal adverse events, adverse reactions to
treatment, non-compliance, withdrawal of consent, or unknown/per-
sonal reasons (Fig. 1). These 108 non-fatal drop-outs, including 35 with
non-fatal adverse events, were equally distributed across treatment
groups (P=0.57) [14] and have been captured in the mortality ana-
lysis, as mortality registration in Denmark is virtually complete.
After 5 years of supplementation, mean (SD) plasma selenium had
risen substantially to 158.3 (28.3), 222.2 (40.6), and 276.5 (78.7) ng/g
in the 100, 200, and 300 µg/d treatment groups, respectively, but was
unchanged at 87.7 (24.2) ng/g in the placebo group (P < 0.001 for
homogeneity of changes from baseline to 5 years across the four
treatment groups) [14].
The average (range) follow-up among survivors was 15.9
(15.5–16.3) years. During 6871 person-years of follow-up, there were
158 deaths, 31 (18 from cancer, 9 from CVD) during the 5 years of
active treatment and 127 (57 from cancer, 34 from CVD) in the 10 years
after treatment cessation (Fig. 1).
All-cause cumulative mortality curves diﬀered signiﬁcantly across
treatment groups (P=0.04 for homogeneity of non-parametric curves)
(Fig. 2A). Participants randomised to 300 µg selenium/d showed a
moderate but non-signiﬁcant increase in mortality after 5 years of
treatment (hazard ratio vs. placebo, 1.62, 95% CI 0.66, 3.96) that was
sustained and became signiﬁcant at the end of the entire follow-up
period (hazard ratio 1.59, 95% CI 1.02, 2.46) (Table 2; Supplemental
Fig. 1A). The 15-year mortality risk-diﬀerence comparing the 300 µg
selenium/d group with placebo was 11.3% (95% CI 0.0, 22.6%)
(Supplemental Fig. 2A). The 100 and 200 µg/d doses showed non-sig-
niﬁcant decreases in all-cause mortality during the 5-year intervention,
but their eﬀects disappeared progressively after treatment cessation
(Table 2; Supplemental Fig. 1A). Adjustment for participant baseline
characteristics did not materially change these ﬁndings.
The eﬀects of selenium supplementation on cancer mortality
(Table 2; Fig. 2B; Supplemental Fig. 2B) and CVD mortality (Table 2;
Fig. 2C; Supplemental Fig. 2C) were similar to those on all-cause
mortality, though diﬀerences in cause-speciﬁc mortality among treat-
ment groups were not signiﬁcant (P=0.10 and 0.19 for homogeneity
of cancer and CVD mortality curves, respectively). The hazard ratios
(95% CIs) for cancer mortality for 300 µg selenium/d vs. placebo were
2.17 (0.65, 7.21) over the 5-year intervention and 1.78 (0.94, 3.34)
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Fig. 2. Cumulative mortality from all causes, cancer, and cardiovascular disease
over time by treatment group. Non-parametric cumulative mortality curves (step
functions) were estimated from Kaplan-Meier methods and compared with the general-
ized Wilcoxon test. Parametric cumulative mortality curves (smooth lines) were estimated
from spline-based parametric survival models with treatment-speciﬁc log cumulative
hazards parameterized as natural cubic splines of log time with knots at the 33th and 67th
percentiles of the uncensored log-time distribution. Cumulative mortality estimates (95%
CIs) at 5, 10, and 15 years of follow-up by treatment group were obtained from spline-
based parametric survival models. Se denotes selenium.
M.P. Rayman et al. Free Radical Biology and Medicine 127 (2018) 46–54
49
over the entire follow-up, while those for CVD mortality were 2.17
(0.40, 11.85) and 1.51 (0.69, 3.33), respectively.
In subgroup analyses, the increased risk of death with 300 µg/d of
selenium supplementation was particularly large in participants, both
men and women< 65 years at randomization, but not in older parti-
cipants (P=0.04 for treatment-by-age interaction; Fig. 3;
Supplemental Table 1). The hazard ratio (95% CI) for all-cause mor-
tality over the entire follow-up for 300 µg selenium/d vs. placebo was
3.12 (1.51, 6.44) in participants< 65 years and 0.93 (0.53, 1.63) in
those ≥ 65 years. No other interactions were statistically signiﬁcant
across subgroups deﬁned by sex, smoking status, body mass index,
Charlson comorbitity index, number of medications, or baseline plasma
selenium.
4. Discussion
A dose of 300 µg/d of selenium (as high-selenium yeast) vs. placebo-
yeast taken for 5 years resulted in a signiﬁcant absolute excess risk of
all-cause mortality of 11.3% (95% CI 0.0, 22.6%) 10 years later in a
country of moderately-low selenium status. Cancer and CVD mortality
similarly appeared to increase, but the eﬀects were not statistically
signiﬁcant. Though the 100 and 200 µg/d doses showed a non-sig-
niﬁcant reduction in mortality during the 5-year treatment period, the
eﬀect had disappeared 10 years post-treatment.
Since excess mortality was observed only with the 300 µg/d dose, it
is unlikely that high concentrations or activity of selenoproteins are
responsible for this adverse eﬀect. Selenoproteins are probably replete
at a plasma selenium concentration of ~ 125 µg/L, at which point the
concentration of selenoprotein P reaches a plateau [3]; this con-
centration was exceeded after 6 months of treatment, having reached
152 ng/g (equivalent to 156 µg/L) even at the lowest dose [14]. The
higher plasma-selenium concentrations achieved in our study, parti-
cularly in the 200 and 300 µg/d treatment groups, thus reﬂect pre-
dominantly non-speciﬁc incorporation of selenomethionine into al-
bumin in place of methionine [3]. We previously obtained interesting
results in a speciation study in a small number of PRECISE participants
that measured the amounts of selenium present in plasma as seleno-
proteins, high-molecular-weight selenium and low-molecular-weight
selenium after 6 months and 5 years of treatment (Deitrich, Rayman,
Moesgard, Goenaga-Infante, unpublished results). While the amount of
selenium in albumin increased markedly from 6 months to 5 years, the
amount present as selenoproteins fell signiﬁcantly at the two highest
dose levels. This implies that long-term treatment with selenium at the
200 or 300 µg/d dose can lead to selenoprotein depletion, potentially
reducing health protection. As supra-nutritional dietary selenium also
depressed selenoprotein expression in animal models [25,26], part of
the harmful eﬀect of high-dose selenium supplementation may be due
to a paradoxical reduction in selenoprotein activity.
The major single component of the selenium-yeast used in our trial
was selenomethionine [27]. By analogy with methionine, seleno-
methionine can be metabolized via the methionine cycle and the trans-
sulphuration pathway to the selenols, selenohomocysteine and seleno-
cysteine [28,29], and can be cleaved to methyl selenol by methioninase,
an enzyme present in many animal and human tissues [30]. Selenols
react with thiols to produce selenyl sulphides/disulphides that can
cause undesirable structural and functional changes, including protein
aggregation, transcription-factor inactivation, and disruption of redox-
regulated cell signalling [31,32]. Selenols, present as selenolates (RSeˉ)
at physiological pH, have the capacity to redox-cycle and generate su-
peroxide radicals thus inducing oxidative stress [28,30] and potentially
increasing the risk of cancer and CVD [33].
Another potential explanation for the harmful eﬀects of supra-
Table 1
Baseline characteristics of trial participants overall and by treatment group.
Selenium dose, µg/d
Characteristic Overall Placebo 100 200 300
No. of participants 491 126 124 122 119
Age, mean (SD), y 66.1 (4.1) 65.4 (3.8) 66.4 (4.1) 66.3 (4.4) 66.5 (4.1)
Sex, Number (%)
Men 255 (51.9) 60 (47.6) 70 (56.5) 66 (54.1) 59 (49.6)
Women 236 (48.1) 66 (52.4) 54 (43.5) 56 (45.9) 60 (50.4)
Smoking status, Number (%)
Never 160 (32.6) 35 (27.8) 42 (33.9) 40 (32.8) 43 (36.2)
Former 185 (37.7) 48 (38.1) 47 (37.9) 52 (42.6) 38 (31.9)
Current 146 (29.7) 43 (34.1) 35 (28.2) 30 (24.6) 38 (31.9)
Body mass index, mean (SD), kg/m2 26.8 (4.1) 26.5 (4.0) 27.1 (4.0) 27.2 (4.3) 26.5 (4.0)
Comorbid conditions, Number (%)
Cardiovascular diseasea 15 (3.1) 2 (1.6) 4 (3.2) 2 (1.6) 7 (5.9)
Chronic pulmonary disease 7 (1.4) 1 (0.8) 2 (1.6) 4 (3.3) 0 (0.0)
Connective tissue disease 6 (1.2) 2 (1.6) 1 (0.8) 2 (1.6) 1 (0.8)
Ulcer disease 14 (2.9) 6 (4.8) 4 (3.2) 0 (0.0) 4 (3.4)
Diabetes mellitus 6 (1.2) 0 (0.0) 4 (3.2) 2 (1.6) 0 (0.0)
Charlson comorbidity index, Number (%)
0 442 (90.0) 115 (91.3) 108 (87.1) 111 (91.0) 108 (90.8)
1–2 49 (10.0) 11 (8.7) 16 (12.9) 11 (9.0) 11 (9.2)
Prescribed medications, Number (%)
Lipid-lowering medication 30 (6.1) 8 (6.3) 12 (9.7) 6 (4.9) 4 (3.4)
Diabetes medication 6 (1.2) 1 (0.8) 3 (2.4) 1 (0.8) 1 (0.8)
Antihypertensive medication 124 (25.4) 31 (24.8) 30 (24.2) 27 (22.5) 36 (30.3)
Thyroid medication 14 (2.9) 2 (1.6) 4 (3.2) 5 (4.1) 3 (2.5)
Glucocorticoids 24 (4.9) 4 (3.2) 9 (7.3) 4 (3.3) 7 (5.9)
Osteoporosis medication 81 (16.6) 26 (20.8) 19 (15.3) 16 (13.3) 20 (16.8)
No. of medications, Number (%)
0 274 (55.8) 72 (57.1) 67 (54.0) 73 (59.8) 62 (52.1)
1 161 (32.8) 37 (29.4) 39 (31.5) 40 (32.8) 45 (37.8)
2–3 56 (11.4) 17 (13.5) 18 (14.5) 9 (7.4) 12 (10.1)
Plasma selenium, mean (SD), ng/g 86.5 (16.3) 86.0 (15.2) 87.5 (16.4) 88.3 (16.2) 83.9 (17.1)
Conversion factor: to convert ng/g values (as measured) for plasma selenium to micrograms per liter, multiply by 1.027.
a Myocardial infarction, congestive heart failure, peripheral vascular disease, or cerebrovascular disease.
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Table 2
Hazard ratios for all-cause, cancer, and cardiovascular disease mortality after the initial 5-year intervention period and the entire follow-up by Ttreatment group.
Selenium dose, µg/d
Outcome Placebo 100 200 300
All-cause mortality
5-year intervention period
No. of deaths/person-years 8/610.1 6/609.4 5/599.8 12/567.6
Mortality ratea (95% CI) 13.1 (6.6, 26.2) 9.8 (4.4, 21.9) 8.3 (3.5, 20.0) 21.1 (12.0, 37.2)
Hazard ratiob (95% CI) 1.00 (Reference) 0.75 (0.26, 2.16) 0.64 (0.21, 1.94) 1.62 (0.66, 3.96)
Entire follow-up
No. of deaths/person-years 35/1766.0 41/1796.8 35/1768.6 47/1539.5
Mortality ratea (95% CI) 19.8 (14.2, 27.6) 22.8 (16.8, 31.0) 19.8 (14.2, 27.6) 30.5 (22.9, 40.6)
Hazard ratiob (95% CI) 1.00 (Reference) 1.15 (0.73, 1.80) 0.99 (0.62, 1.59) 1.59 (1.02, 2.46)
Cancer mortality
5-year intervention period
No. of deaths/person-years 4/610.1 3/609.4 3/589.8 8/562.6
Mortality ratea (95% CI) 6.6 (2.5, 17.5) 4.9 (1.6, 15.3) 5.1 (1.6, 15.8) 14.2 (7.1, 28.4)
Hazard ratiob (95% CI) 1.00 (Reference) 0.75 (0.17, 3.36) 0.77 (0.17, 3.46) 2.17 (0.65, 7.21)
Entire follow-up
No. of deaths/person-years 16/1766.0 20/1796.8 15/1748.5 24/1524.6
Mortality ratea (95% CI) 9.1 (5.6, 14.8) 11.1 (7.2, 17.3) 8.6 (5.2, 14.2) 15.7 (10.6, 23.5)
Hazard ratiob (95% CI) 1.00 (Reference) 1.22 (0.63, 2.36) 0.94 (0.46, 1.90) 1.78 (0.94, 3.34)
Cardiovascular disease mortality
5-year intervention period
No. of deaths/person-years 2/610.1 2/609.4 1/589.8 4/562.6
Mortality ratea (95% CI) 3.3 (0.8, 13.1) 3.3 (0.8, 13.1) 1.7 (0.2, 12.0) 7.1 (2.7, 18.9)
Hazard ratiob (95% CI) 1.00 (Reference) 1.00 (0.14, 7.11) 0.52 (0.05, 5.72) 2.17 (0.40, 11.85)
Entire follow-up
No. of deaths/person-years 11/1766.0 7/1796.8 11/1748.5 14/1524.6
Mortality ratea (95% CI) 6.2 (3.4, 11.2) 3.9 (1.9, 8.2) 6.3 (3.5, 11.4) 9.2 (5.4, 15.5)
Hazard ratiob (95% CI) 1.00 (Reference) 0.62 (0.24, 1.61) 1.00 (0.44, 2.31) 1.51 (0.69, 3.33)
a Mortality rates and 95% CIs per 1000 person-years.
b Hazard ratios and 95% CIs for the three active treatment groups compared to placebo were obtained from Cox proportional hazards models after the initial 5-year intervention period
and the entire follow-up.
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Hazard ratio for all−cause mortality over the entire follow−up (95% CI)
Se 100 µg/d vs. placebo
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1.09 (0.53, 2.22)
0.61 (0.30, 1.22)
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0.2 0.5 1 2 5
3.12 (1.51, 6.44)
0.93 (0.53, 1.63)
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1.52 (0.74, 3.14)
2.04 (1.12, 3.71)
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Se 300 µg/d vs. placebo
Fig. 3. Hazard ratios for all-cause mortality over the entire follow-up period comparing the three active treatment groups with placebo by baseline subgroup. Subgroup-
speciﬁc hazard ratios (squares with area inversely proportional to the variance) and their 95% CIs (horizontal lines) were obtained from Cox proportional hazards models with interaction
terms between treatment groups and the corresponding subgroup indicator. Se denotes selenium.
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nutritional selenium is its eﬀect on protein folding in the endoplasmic
reticulum (ER). Selenolates are highly redox active and can eﬀect thiol-
disulphide interchange in proteins resulting in protein misfolding or
unfolding [31,34], causing ER stress and triggering the unfolded-pro-
tein response (UPR), a complex signalling network that attempts to
restore homeostasis [35]. Indeed, treatment of cultured endothelial
cells with 5 µM (400 µg/L) selenium (as selenite), a concentration of the
same order of magnitude as the plasma level achieved in the 300 µg/d
group (284 µg/L), enhanced mRNA expression of several ER-stress
markers, reduced nitric-oxide production, induced superoxide genera-
tion and impaired angiogenesis [36]. However, the relevance of this
comparison is doubtful as the selenium-treatment species were dif-
ferent. As both ER stress and UPR activation are implicated in many
human cancer types and UPR activation has recently been shown to be
a vital step in cancer development [37], the induction of ER stress and
UPR activation might explain the signiﬁcant excess mortality in the
300 µg/d group. Furthermore, selenium compounds can induce DNA
damage and, owing to their reactivity with thiols [31], can interfere
with the integrity or function of DNA repair proteins [38], potentially
increasing cancer risk.
Kinetic studies have shown that high-dose selenomethionine toxi-
city persists for ≥ 5 years after supplementation is stopped, as seleno-
methionine is extensively recycled with a whole-body turn-over time of
363 days [39]. That extended length of exposure resulting from re-
utilisation of selenomethionine-selenium may explain the increased
mortality 10 years after treatment cessation. Supplementation with
sodium selenite, which is either immediately used for selenoprotein
synthesis or excreted [40], might not have increased mortality.
In our study, excess mortality with the 300 µg/d selenium dose was
concentrated in younger participants. While this may be a chance
ﬁnding owing to multiple subgroup analyses, there is a possible
methodological explanation, and several mechanistic explanations. The
methodological explanation is that when a population already elderly
at baseline is followed up for a long time, we can expect that mortality
curves for the sub-groups will converge at the end of the follow-up.
Thus HRs after 15 years will provide downwardly biased estimates of
the underlying treatment eﬀects; this ceiling eﬀect would be more
marked in older participants. With regard to mechanistic explanations,
it is possible that age-related diﬀerences that aﬀect methionine/sele-
nomethionine metabolism [29,41], could account for these ﬁndings,
e.g., changes in gut microbiota [42] that can metabolise seleno-
methionine [41] or in functional vitamin-B12 status aﬀecting 1-carbon
metabolism [43] that is more likely to be identiﬁed and addressed in
older participants. A further possibility, relates to the known loss of
muscle with increasing age (sarcopenia). Whole-body turnover of se-
lenium is determined largely by peripheral tissues including skeletal
muscle which contribute 60% to total body selenium content [39]. As
muscle mass declines with age [44,45], older participants may be less
able to accumulate selenomethionine in muscle tissue, reducing the
possibility of its reutilisation, hence lessening exposure. Alternatively,
there may simply be stronger competing risk factors in the older age-
group.
Our study has limitations: mortality was not the primary endpoint of
the Denmark PRECISE Trial but was adopted when further funding
enabled the intervention to continue for 5 years, hence the need for
cautious interpretation of our ﬁndings, as they result from post-hoc
analyses; it was conducted in apparently healthy elderly, so the results
may not extend to other age groups or participants with diﬀerent co-
morbidities; 108 live participants (22.0%) dropped out before com-
pleting the 5-year intervention period, though they were equally dis-
tributed between treatment groups and captured in the intention-to-
treat mortality analysis; there was only a small diﬀerence in the number
of deaths (35 in the placebo group vs. 47 in the 300 µg group). An
additional limitation is the lack of any measurement of selenium status
in the ﬁnal 10 years of follow-up after cessation of supplementation.
Importantly, we cannot rule out the role of chance in our ﬁndings as the
sample size was small and the study was not originally designed to
assess long-term mortality. Nonetheless, as the only long-term, rando-
mised, controlled, trial of selenium as a single agent at diﬀerent dose
levels in a non-selenium-replete population, with complete ascertain-
ment of mortality [22,23], the results make a contribution to the overall
evidence base.
The eﬀects of selenium supplementation depend on dose (including
dietary intake), selenium species, and duration of treatment. Our results
are compatible with a U-shaped dose-response relationship between
selenium intake or status and health outcomes, previously shown in
observational studies [1]. At low selenium intake, additional selenium
may confer protection by increasing the concentration or activity of
antioxidant selenoproteins. However, when selenium intake is already
adequate, additional selenium can become toxic, at least partly through
the generation of superoxide, as described above [29,31,32,36]. A
plasma selenium concentration of ~ 125 µg/L is probably suﬃcient to
replete the selenoproteins [3], and a concentration of 228 µg/L, the
level attained in our study after dosing with 200 µg/d for 5 years, ap-
peared to be without harm and may even have aﬀorded some beneﬁt. A
dose of 200 µg/d of selenium, as selenomethionine, in SELECT, where
participants had a higher background selenium intake (baseline serum/
plasma selenium 136 vs. 91 µg/L), resulted in a serum-selenium con-
centration of 252 µg/L at 4 years and recognised symptoms of selenium
toxicity after 5.5 years, i.e., RR (95% CI), alopecia 1.28 (1.01, 1.62) and
dermatitis 1.17 (1.0, 1.35), though there was no increase in mortality
[12,13]. In our study, a dose of 300 µg/d of selenium, as selenium-yeast
(54–60% selenomethionine) [14] raised plasma selenium to the higher
value of 284 µg/L at 5 years and signiﬁcantly increased mortality some
10 years later. These results suggest that a total intake (diet plus sele-
nomethionine-containing supplement) exceeding 300 µg/d for 5 years
or more should be avoided.
Our ﬁndings may have particular implications for supplement takers
who may more readily exceed an intake of 300 µg/d. People with de-
ﬁcient or marginally-deﬁcient selenium status may beneﬁt from addi-
tional selenium intake [1], depending on their baseline level and dose.
While supplementation with 200 µg selenium/d may be safe in Danes or
those with similar baseline selenium status, such as many Europeans,
the same cannot be assumed in countries with higher baseline status,
such as North America. In NHANES 2003–4 [46], a representative
survey of the US population, mean serum-selenium concentration was
137 µg/L, indicating selenoprotein repletion [4]. Under these circum-
stances, an additional 200 µg selenium/d in a US adult may result in
selenium toxicity [12] and a potentially greater risk of mortality if that
intake is continued beyond 5.5 years. It would be interesting to examine
mortality in SELECT men in 2018, by which time they will have had 10
years of follow-up, post-treatment, as in Denmark PRECISE. In the
meantime, despite their limitations, our ﬁndings suggest that the public
should avoid high-dose selenium supplements, particularly in countries
with an adequate background selenium intake.
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